These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1245 related items for PubMed ID: 11095440

  • 1. Growth hormone replacement therapy improves body composition and increases bone metabolism in elderly patients with pituitary disease.
    Fernholm R, Bramnert M, Hägg E, Hilding A, Baylink DJ, Mohan S, Thorén M.
    J Clin Endocrinol Metab; 2000 Nov; 85(11):4104-12. PubMed ID: 11095440
    [Abstract] [Full Text] [Related]

  • 2. Serum insulin-like growth factor I (IGF-I), IGF-binding protein-1 and -3, and the acid-labile subunit as serum markers of body composition during growth hormone (GH) therapy in adults with GH deficiency.
    Thorén M, Hilding A, Baxter RC, Degerblad M, Wivall-Helleryd IL, Hall K.
    J Clin Endocrinol Metab; 1997 Jan; 82(1):223-8. PubMed ID: 8989263
    [Abstract] [Full Text] [Related]

  • 3. Recombinant growth hormone (GH) therapy in GH-deficient adults: a long-term controlled study on daily versus thrice weekly injections.
    Amato G, Mazziotti G, Di Somma C, Lalli E, De Felice G, Conte M, Rotondi M, Pietrosante M, Lombardi G, Bellastella A, Carella C, Colao A.
    J Clin Endocrinol Metab; 2000 Oct; 85(10):3720-5. PubMed ID: 11061530
    [Abstract] [Full Text] [Related]

  • 4. Baseline characteristics and effects of growth hormone therapy over two years in younger and elderly adults with adult onset GH deficiency.
    Franco C, Johannsson G, Bengtsson BA, Svensson J.
    J Clin Endocrinol Metab; 2006 Nov; 91(11):4408-14. PubMed ID: 16940452
    [Abstract] [Full Text] [Related]

  • 5. Serum levels of insulin-like growth factor binding proteins (IGFBP)-4 and -5 correlate with bone mineral density in growth hormone (GH)-deficient adults and increase with GH replacement therapy.
    Thorén M, Hilding A, Brismar T, Magnusson P, Degerblad M, Larsson L, Sääf M, Baylink DJ, Mohan S.
    J Bone Miner Res; 1998 May; 13(5):891-9. PubMed ID: 9610754
    [Abstract] [Full Text] [Related]

  • 6. Growth hormone replacement therapy in the elderly with hypothalamic-pituitary disease: a dose-finding study.
    Toogood AA, Shalet SM.
    J Clin Endocrinol Metab; 1999 Jan; 84(1):131-6. PubMed ID: 9920073
    [Abstract] [Full Text] [Related]

  • 7. High serum IGFBP-2 is predictive of increased bone turnover in aging men and women.
    Amin S, Riggs BL, Melton LJ, Achenbach SJ, Atkinson EJ, Khosla S.
    J Bone Miner Res; 2007 Jun; 22(6):799-807. PubMed ID: 17352648
    [Abstract] [Full Text] [Related]

  • 8. Discontinuing long-term GH replacement therapy--a randomized, placebo-controlled crossover trial in adult GH deficiency.
    Filipsson Nyström H, Barbosa EJ, Nilsson AG, Norrman LL, Ragnarsson O, Johannsson G.
    J Clin Endocrinol Metab; 2012 Sep; 97(9):3185-95. PubMed ID: 22791760
    [Abstract] [Full Text] [Related]

  • 9. Influence of growth hormone on whole body and regional soft tissue composition in adult patients on hemodialysis. A double-blind, randomized, placebo-controlled study.
    Hansen TB, Gram J, Jensen PB, Kristiansen JH, Ekelund B, Christiansen JS, Pedersen FB.
    Clin Nephrol; 2000 Feb; 53(2):99-107. PubMed ID: 10711411
    [Abstract] [Full Text] [Related]

  • 10. Growth hormone, insulin-like growth factors and their binding proteins in adult hemodialysis patients treated with recombinant human growth hormone.
    Jensen PB, Hansen TB, Frystyk J, Ladefoged SD, Pedersen FB, Christiansen JS.
    Clin Nephrol; 1999 Aug; 52(2):103-9. PubMed ID: 10480221
    [Abstract] [Full Text] [Related]

  • 11. Safety and efficacy of growth hormone (GH) during extended treatment of adult Japanese patients with GH deficiency (GHD).
    Chihara K, Kato Y, Kohno H, Takano K, Tanaka T, Teramoto A, Shimatsu A.
    Growth Horm IGF Res; 2008 Aug; 18(4):307-17. PubMed ID: 18282776
    [Abstract] [Full Text] [Related]

  • 12. Growth hormone (GH)-deficient men are more responsive to GH replacement therapy than women.
    Burman P, Johansson AG, Siegbahn A, Vessby B, Karlsson FA.
    J Clin Endocrinol Metab; 1997 Feb; 82(2):550-5. PubMed ID: 9024252
    [Abstract] [Full Text] [Related]

  • 13. Endocrine and metabolic effects of long-term administration of [Nle27]growth hormone-releasing hormone-(1-29)-NH2 in age-advanced men and women.
    Khorram O, Laughlin GA, Yen SS.
    J Clin Endocrinol Metab; 1997 May; 82(5):1472-9. PubMed ID: 9141536
    [Abstract] [Full Text] [Related]

  • 14. The effect of the deterioration of insulin sensitivity on beta-cell function in growth-hormone-deficient adults following 4-month growth hormone replacement therapy.
    Rosenfalck AM, Fisker S, Hilsted J, Dinesen B, Vølund A, Jørgensen JO, Christiansen JS, Madsbad S.
    Growth Horm IGF Res; 1999 Apr; 9(2):96-105. PubMed ID: 10373342
    [Abstract] [Full Text] [Related]

  • 15. The effects of GH replacement therapy on cardiac morphology and function, exercise capacity and serum lipids in elderly patients with GH deficiency.
    Elgzyri T, Castenfors J, Hägg E, Backman C, Thorén M, Bramnert M.
    Clin Endocrinol (Oxf); 2004 Jul; 61(1):113-22. PubMed ID: 15212653
    [Abstract] [Full Text] [Related]

  • 16. Withdrawal of long-term physiological growth hormone (GH) administration: differential effects on bone density and body composition in men with adult-onset GH deficiency.
    Biller BM, Sesmilo G, Baum HB, Hayden D, Schoenfeld D, Klibanski A.
    J Clin Endocrinol Metab; 2000 Mar; 85(3):970-6. PubMed ID: 10720025
    [Abstract] [Full Text] [Related]

  • 17. Bone mineral content and bone metabolism during physiological GH treatment in GH-deficient adults--an 18-month randomised, placebo-controlled, double blinded trial.
    Sneppen SB, Hoeck HC, Kollerup G, Sørensen OH, Laurberg P, Feldt-Rasmussen U.
    Eur J Endocrinol; 2002 Feb; 146(2):187-95. PubMed ID: 11834427
    [Abstract] [Full Text] [Related]

  • 18. Serum leptin response to the acute and chronic administration of growth hormone (GH) to elderly subjects with GH deficiency.
    Gill MS, Toogood AA, Jones J, Clayton PE, Shalet SM.
    J Clin Endocrinol Metab; 1999 Apr; 84(4):1288-95. PubMed ID: 10199769
    [Abstract] [Full Text] [Related]

  • 19. Skeletal effects of two years of treatment with low physiological doses of recombinant human growth hormone (GH) in patients with adult-onset GH deficiency.
    Janssen YJ, Hamdy NA, Frölich M, Roelfsema F.
    J Clin Endocrinol Metab; 1998 Jun; 83(6):2143-8. PubMed ID: 9626153
    [Abstract] [Full Text] [Related]

  • 20. The individual responsiveness to growth hormone (GH) treatment in GH-deficient adults is dependent on the level of GH-binding protein, body mass index, age, and gender.
    Johannsson G, Bjarnason R, Bramnert M, Carlsson LM, Degerblad M, Manhem P, Rośen T, Thorén M, Bengtsson BA.
    J Clin Endocrinol Metab; 1996 Apr; 81(4):1575-81. PubMed ID: 8636370
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 63.